Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor
(TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free
remission (TFR).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
H. Jean Khoury Cure CML Consortium Incyte Corporation